25 Apr
Press Release

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Expanding Its Direct Distribution Network to National And Regional Wholesalers And Pharmacies 

PALO ALTO, CA. April 25, 2022 /Newswire/ -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused...

Read more

12 Apr
Press Release

Scilex Holding Company a majority-owned subsidiary of Sorrento Therapeutics, Inc., Strengthens Board of Directors with Appointment of Highly Accomplished Pharmaceutical and Biotechnology Executive, Laura Hamill

PALO ALTO, CA. April 12, 2022 /Newswire/ -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused...

Read more

04 Apr
Press Release

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announces continuous sales growth in ZTlido® with preliminary gross sales of approximately $8.1 million during the month of March 2022 and $18.4 million for 1Q2022

ZTlido 53% year-over-year preliminary unaudited gross sales in March 2022Select payor accounts representing approximately 200 million of the over 300 million covered lives across the United States PALO ALTO,...

Read more

25 Mar
Press Release

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., enters into a Non-Binding Term Sheet for a $5 Billion Committed Equity Financing Facility to be Effective in Connection with the Closing of the Merger with Vickers Vantage Corp. I

PALO ALTO, CA. March 25, 2022 /Newswire/ -- Scilex Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid...

Read more

«‹2223242526›»